反応式
[NH:1]1[C:9]2[C:4](=[CH:5][C:6]([N:10]3[C:14]4=[N:15][CH:16]=[CH:17][CH:18]=[C:13]4[N:12]([CH2:19][CH3:20])[C:11]3=[O:21])=[CH:7][CH:8]=2)[CH2:3][CH2:2]1.Cl[C:23]1[N:27](COCC[Si](C)(C)C)[C:26]2[CH:36]=[CH:37][CH:38]=[CH:39][C:25]=2[N:24]=1>CN1C(=O)CCC1>[NH:24]1[C:25]2[CH:39]=[CH:38][CH:37]=[CH:36][C:26]=2[N:27]=[C:23]1[N:1]1[C:9]2[C:4](=[CH:5][C:6]([N:10]3[C:14]4=[N:15][CH:16]=[CH:17][CH:18]=[C:13]4[N:12]([CH2:19][CH3:20])[C:11]3=[O:21])=[CH:7][CH:8]=2)[CH2:3][CH2:2]1参加物
4
反応条件
- 温度
- 120 °C
実験手順
A mixture of 3-(2,3-dihydro-1H-indol-5-yl)-1-ethyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one obtained from example 13e) and 2-chloro-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-benzimidazole (108 mg) in NMP (2.0 mL) was stirred at 120° C. for 12 h, treated with sat.NaHCO3aq. and extracted with AcOEt. The organic layer was dried over MgSO4 and concentrated in vacuo. The residue was purified by preparative HPLC and crystallized from AcOEt/Hexane to give 3-[1-(1H-benzimidazol-2-yl)-2,3-dihydro-1H-indol-5-yl]-1-ethyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (12 mg).
後処理
- additiontreated with sat.NaHCO3aq
- extractionand extracted with AcOEt
- dry with materialThe organic layer was dried over MgSO4
- concentrationconcentrated in vacuo
- customThe residue was purified by preparative HPLC
- customcrystallized from AcOEt/Hexane
出典と根拠
- ORDレコード
- ord-b7448e689c7e4368ada9fc656bddba5f
- 出典データセット
- uspto-grants-2016_01
- 特許番号
- US09226921B2
関連ノート
読み込み中…